Edition:
United States

Oncopeptides AB (ONCO.ST)

ONCO.ST on Stockholm Stock Exchange

80.00SEK
23 Feb 2018
Change (% chg)

1.30kr (+1.65%)
Prev Close
78.70kr
Open
79.40kr
Day's High
80.00kr
Day's Low
78.60kr
Volume
10,768
Avg. Vol
44,723
52-wk High
96.00kr
52-wk Low
41.10kr

Chart for

About

Oncopeptides AB is a Sweden-based clinical development pharmaceutical company, which is primarily engaged in the healthcare industry. The Company focuses on research and development of cancer treatment solutions. The Company's product Ygalo is a peptidase potentiated alkylator, a type of cytotoxic drug that is targeted for use... (more)

Overall

Beta: --
Market Cap(Mil.): kr3,132.73
Shares Outstanding(Mil.): 39.81
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Oncopeptides Q4 Net Loss Up At Sek ‍66.7​ Million

* Q4 NET LOSS SEK ‍66.7​ MILLION VERSUS LOSS SEK 51.1 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 22 2018

BRIEF-Oncopeptides Q3 operating ‍loss widens to SEK 51.6 million

* Q3 OPERATING ‍LOSS SEK 51.6 MILLION VERSUS LOSS SEK 24.7 MILLION YEAR AGO​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 15 2017

BRIEF-Oncopeptides Q2 loss for period widens to SEK 67.3 mln​

* ‍Q2 LOSS FOR PERIOD WAS 67.3 (LOSS: 23.5) MSEK​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 25 2017

Earnings vs. Estimates